Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer.
Winquist E, Hotte SJ, Chi K, Sridhar S, Ellard S, Ong M, Iqbal N, Salim M, Emmenegger U, Gingerich JR, Lalani AK, Major P, Kollmannsberger C, Yip S, Hansen A, Finch D, Canil C, Hutchenreuther J, Vera-Badillo F, Smoragiewicz M, Cabanero M, Tsao MS, Ritch E, Wyatt AW, Seymour L. Winquist E, et al. Among authors: smoragiewicz m. Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-1612. Online ahead of print. Clin Cancer Res. 2024. PMID: 39513948
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
Nehra J, Bradbury PA, Ellis PM, Laskin J, Kollmannsberger C, Hao D, Juergens RA, Goss G, Wheatley-Price P, Hotte SJ, Gelmon K, Tinker AV, Brown-Walker P, Gauthier I, Tu D, Song X, Khan A, Seymour L, Smoragiewicz M. Nehra J, et al. Among authors: smoragiewicz m. Invest New Drugs. 2020 Oct;38(5):1442-1447. doi: 10.1007/s10637-020-00904-7. Epub 2020 Feb 4. Invest New Drugs. 2020. PMID: 32020438 Clinical Trial.
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.
Juergens RA, Hao D, Ellis PM, Tu D, Mates M, Kollmannsberger C, Bradbury PA, Tehfe M, Wheatley-Price P, Robinson A, Bebb G, Laskin J, Goffin J, Hilton J, Tomiak A, Hotte S, Goss GD, Brown-Walker P, Sun X, Tsao MS, Cabanero M, Gauthier I, Song X, Dennis PA, Seymour LK, Smoragiewicz M, Laurie SA. Juergens RA, et al. Among authors: smoragiewicz m. Lung Cancer. 2020 May;143:1-11. doi: 10.1016/j.lungcan.2020.02.016. Epub 2020 Feb 28. Lung Cancer. 2020. PMID: 32169783 Clinical Trial.
Editorial Comment.
Smoragiewicz M, Emmenegger U. Smoragiewicz M, et al. J Urol. 2021 May;205(5):1370. doi: 10.1097/JU.0000000000001568.01. Epub 2021 Mar 11. J Urol. 2021. PMID: 33705221 No abstract available.
Editorial Comment.
Smoragiewicz M, Emmenegger U. Smoragiewicz M, et al. J Urol. 2023 Jun;209(6):1130. doi: 10.1097/JU.0000000000003370.02. Epub 2023 Mar 23. J Urol. 2023. PMID: 36950912 No abstract available.
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK. Kaymakcalan MD, et al. Among authors: smoragiewicz m. Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5. Cancer. 2016. PMID: 26540173 Free article.
31 results